Alimera Science (NASDAQ:ALIM) announces that the United Kingdom National Institute for Health and Care Excellence recommended funding for Iluvien 190 micrograms intravitreal implant in applicator for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment.
The National Health Service will pay for Iluvien prescriptions for the treatment of NIPU as part of its offering. Iluvien is also funded for the treatment of diabetic macular edema in the United Kingdom.
ALIM +30.44% premarket to $1.20.
Source: Press Release
Subscribe for full text news in your inbox